clinical trial · NCT04893239
Exploratory Study to Assess Delivery of LMN-201 Components Via Enteric Capsules in the Gut of Individuals With Ostomies
Lumen Bioscience, Inc.·phase1·completed·n = 12
C. Diff. InfectionsLMN-201 Anti-toxin B VHH-1LMN-201 Anti-toxin B VHH-2LMN-201 Anti-toxin B VHH-3LMN-201 Anti-toxin B VHH-1, VHH-2, VHH-3
brief summary
This is a Phase 1, single-site, open label, exploratory study to assess delivery of LMN-201 components via enteric capsules in the gut of individuals with ostomies.
started
Aug 18, 2021
primary completion
Feb 23, 2022
completion
Feb 23, 2022
last updated
Mar 18, 2025
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol